Purchase this article with an account.
Francisco J Rodriguez, Shirley Margarita Rosenstiehl, Diana Alejandra Cortes, Claudia Rosa Carvajal; Results of Aflibercept in Hispanics with retinal vein occlusion macular edema. Invest. Ophthalmol. Vis. Sci. 2018;59(9):397.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Introduction:Retinal vein occlusion (RVO) can cause vision loss secondary to macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF). Propose: To describe the functional and anatomic results of intravitreal afliberceptfor macular edema associated to retinal vein occlusion in a Hispanic population
Methods: Retrospective chart and ancillary tests review of patients with either central (CRVO) or branch (BRVO) retinal vein occlusion and associated macular edema (ME) treated with aflibercept at Fundacion Oftalmologica Nacional.
Results: 17 eyes of seventeen patients with a mean age of 54 years (SD 15.4), 64.7% men were included. CRVO was present in 58.8% patients and BRVO in 41.2%. A mean of 5 injections (range 3-9) of aflibercept were performed. Average follow-up was 8 months (range 3-25 months). Aflibercept was used de novo in 94% of the treated eyes. The visual acuity improved at least 1 line in 72% of the eyes, 36% gained ≥ 3 lines. The optical coherence central macular thickness before injections was 521 μ (250-988 μ), and 249 μ at the last follow-up visit, with an average change of 272 μ (p = 0.015).
Conclusions: Visual acuity improved or remained stable in most of the treated eyes and there was anatomic improvement in all eyes treated with Aflibercept in short and long follow-up time.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only